Our Product Platforms include Active ImmunoTherapies and Antibody ImmunoTherapies:

Cancer Stem Cell Vaccines, which are peptide-based vaccines that are non patient-specific, off-the-shelf vaccines that have the ability to target multiple cancers. We expect to file an Investigational New Drug (IND) application in the third quarter of 2009 to begin a Phase 1 clinical trial.

Cancer Antigen Vaccines, which are dendritic cell-based vaccines designed to elicit persistent and targeted T cell immune responses against the patient's cancer. A Phase I human clinical trial for glioblastoma (brain cancer) has been completed. Antibody ImmunoTherapies, which include both monoclonal antibody candidates and a platform that allows the discovery of targets (antigens) and monoclonal antibodies for the diagnosis and treatment of cancer. We are seeking licensees or partners for the further development of this program.